When the enzyme, called pyruvate kinase M2 or PKM2, is released by immune cells, it promotes the development of new blood cells at the site of injury, according to lead author Zhi-Ren Liu, PhD.
“We could easily imagine PKM2 being used for wound dressing, ” said Dr. Liu. “It could also likely be used for binding wounds. For example, when you’ve transplanted skin from a donor, sometimes this new skin doesn’t attach well because of immune rejection, so therefore, it’s easy to fail, especially if it’s a large transplant. “
Dr. Liu also said PKM2 could help heal internal surgical incisions. The findings were published in the journal Wound Repair and Regeneration.
More articles on wound care:
8 reasons why all hospitals need a wound care strategy
VA adds Crawford Healthcare wound and skin care products to Federal Supply Schedule
Want to fight drug-resistant superbugs? Have a glass (or goblet) of mead
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.